Non-small cell lung cancer exhibits substantial histological and molecular heterogeneity. Alterations involving EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, HER2, and other oncogenic drivers can continuously activate tumor-cell proliferation and survival signaling and generate molecular subtypes with ...
Tumor organoids can retain some of the histological features, driver alterations, and clonal differences of a patient’s tumor, providing expandable human-derived models for studying tumor evolution, therapeutic sensitivity, and mechanisms of drug resistance.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.